

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<i>In re</i> Application of)	
)	Group Art Unit: 1626
Michael L. VAZQUEZ <i>et al.</i>)	
)	Examiner: Ebenezer O. Sackey
Serial No. 10/689,513)	
)	Atty. Docket 101765.00016 (2751/5)
Filed: October 21, 2003)	

For: α - AND β -AMINO ACID HYDROXYETHYLAMINO SULFONYL UREA DERIVATIVES USEFUL AS RETROVIRAL PROTEASE INHIBITORS

TERMINAL DISCLAIMER UNDER 37 C.F.R. § 1.321(c)


U.S. Patent and Trademark Office
Customer Service Window, Mail Stop Amendment
401 Dulany Street
Alexandria, VA 22314

Sir:

The co-owners of the complete interest in the subject application [Monsanto Company (now named Pharmacia Corporation) and G.D. Searle & Co. (now named G.D. Searle, LLC, which is a wholly owned subsidiary of Pharmacia Corporation), which are now both owned by Pfizer, Inc.], by virtue of an assignment of original application Serial No. 07/968,712, recorded at (1) Reel/Frame 6406/0172 for inventor VAZQUEZ; (2) Reel/Frame 6406/0174 for inventor MUELLER; (3) Reel/Frame 6406/0176 for inventor SUN; and (4) Reel/Frame 6406/0178 for inventors TALLEY, GETMAN and DeCRESCENZO, hereby disclaim, except as provided below, the terminal part of the statutory term of any patent granted on the subject application, which would extend beyond the expiration dates of the full statutory term defined in 35 U.S.C. §§ 154-156 and 173 of (1) U.S. Patent 5,578,606; (2) U.S. Patent 6,022,872; (3) U.S. Patent 6,211,176; (4) U.S. Patent 6,403,585; and (5) U.S. Patent 6,683,648.

The co-owners hereby agree that any patent so granted on the subject application shall be enforceable only for and during such period that said patent and said U.S. Patents 5,578,606; 6,022,872; 6,211,176; 6,403,585; and 6,683,648 remain commonly owned. This agreement runs

Michael L. VAZQUEZ *et al.*
U.S. Patent Application Serial No. 10/689,513



Attorney Docket No. 101765.00016
(2751/5)

with any patent granted on the subject application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the co-owners do not disclaim the terminal part of any patent granted on the subject application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §§ 154-156 and 173 of said U.S. Patent 5,578,606; U.S. Patent 6,022,872; U.S. Patent 6,211,176; U.S. Patent 6,403,585; or U.S. Patent 6,683,648 in the event that one or more of such patents: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.


The undersigned is an Attorney of Record.

The Commissioner is hereby authorized to charge the \$130 fee under 37 C.F.R. § 1.20(d) to Deposit Account No. 19-0733. In the event that any variance exists between the amount indicated and the amount authorized by the undersigned, the Commissioner is authorized to charge to our Deposit Account No. 19-0733, as necessary.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted,

Date: 3-15-2005

By: 

Joseph M. Skerpon
Attorney of Record
Registration No. 29,864

BANNER & WITCOFF, LTD.
1001 G Street, NW
Washington, DC 20001
(202) 824-3000